Zantrene Improves Immune Therapy Treatment of Melanoma
Filed with ASX · · 11 pages · English
Earlier from Racura Oncology
- Race Oncology Announces On-Market Share Buyback
- EMD AML MDS Trial Expands to Europe
- Zantrene AML trial in Israel advances to Phase 2
- Race Receives Governance Approval for AML EMD & MDS Trial
- Race receives Human Ethics AML Trial Approval
Later from Racura Oncology
- Zantrene shows synergy with kinase inhibitors in melanoma
- Zantrene Protects Mouse Hearts from Chemotherapy Damage
- Race Oncology: Quarterly Activity Report & Appendix 4C
- Race Oncology: RAC Quarterly Investor Presentation
- Race Oncology: Update - Notification of buy-back - RAC
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology